Skip to main content

Table 7 Carrier study exploratory clinical efficacy assessments: change from parent study baseline to extension week 52

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

  3003 ApoE ε4 carrier study
PBO + BAP 0.5 (n = 199) BAP 0.5 + BAP 0.5 (n = 256)
ADAS-Cog, LS mean (SE) 10.12 (0.75) 10.11 (0.63)
 LS mean difference 0.00; P = 0.996
DAD, LS mean (SE) –20.96 (1.65) –22.72 (1.36)
 LS mean difference –1.75; P = 0.412
NPI, LS mean (SE) 4.32 (0.96) 3.52 (0.80)
 LS mean difference –0.80; P = 0.524
MMSEa, LS mean (SE) –4.44 (0.26) –4.26 (0.21)
 LS mean difference 0.18; P = 0.598
  1. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive Subscale, ApoE apolipoprotein E, BAP bapineuzumab, DAD Disability Assessment Scale for Dementia, LS least squares, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, PBO placebo, SE standard error of the mean
  2. aDifference in MMSE score was between parent study baseline and extension study week 45